Antitumor vaccination effect of dendritic cells can be augmented by locally utilizing Th1-type cytokines from OK432-reactive CD4+ T cells

Cancer Immunology Immunotherapy

Volumn 46, Issue 3, 1998, Pages 128-136

  Tamada, Koji ^a   Harada, Mamoru ^a   Abe, Koichiro ^a   Li, Tieli ^a   Tada, Hitoshi ^a   Onoe, Yasuhiro ^a   Nomoto, Kikuo ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Antitumor vaccination; Cytokine help; Dendritic cells; OK432; Tumor peptide

Indexed keywords

CD4 ANTIGEN; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 4; PEPTIDE; PICIBANIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; BONE MARROW CELLS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CELL COMMUNICATION; CYTOKINES; DENDRITIC CELLS; FEMALE; IMMUNOPHENOTYPING; INTERFERON TYPE II; INTERLEUKIN-12; LYMPHOCYTE ACTIVATION; MAST-CELL SARCOMA; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; PICIBANIL; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS; TUMOR CELLS, CULTURED; VACCINATION;

EID: 0031866234     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050471     Document Type: Article

References (38)

1. Bianchi R, Grohmann U, Belladonna ML, Silla S, Fallarino F, Ayroldi E, Fioretti MC, Puccetti P (1996) IL-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells. J Immunol 157:1589
2. Boon T, Cerottini JC, Van den Eynde B, Van der Bruggen P, Van Pel A (1994) Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12:337
3. Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lunzavecchia A, Alber G (1996) Ligation of CD40 on dendritic cells triggers production of high level of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 184:747
4. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD (1996) Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity. J Exp Med 183:283
5. Cohen PJ, Cohen PA, Rosenberg SA, Katz SI, Mule JJ (1994) Murine epidermal langerhans cells and splenic dendritic cells present tumor-associated antigens to primed T cells. Eur J Immunol 24:315
6. Fearon E, Pardoll D, Itaya T, Golumbek P, Levitsk H, Simons J, Karasuyama H, Vogelstein B, Frost P (1990) Interleukin-2 production by tumor cells bypasses helper function in the generation of an antitumor response. Cell 60:397
7. - or helper peptides in priming for skin test reactivity to a P815AB-related peptide. Eur J Immunol 25:2797
8. Imaishi K, Igarashi H, Ushiyama T (1990) Activation of murine T cells by streptococcal pyrogenic exotoxin type A, requirement for MHC class II molecules on accessory cells and identification of Vβ elements in T cell receptor of toxin reactive T cells. J Immunol 145:3170
9. Inaba K, Metlay JP, Crowley MT, Steinman RM (1990) Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ. J Exp Med 172:631
10. Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, Marumatsu S, Steinman R M (1992) Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 176:1693
11. Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S, Loudon R, Sherrnan F, Perussia B, Trinchieri G (1989) Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 170:827
12. Kurosawa S, Harada M, Shinomiya Y, Terao H, Nomoto K (1996) The concurrent administration of OK432 augments the antitumor vaccination effect with tumor cells by sustaining locally infiltrating natural killer cells. Cancer Immunol Immunother 43:31
13. Lethe B, Van den Eynde B, Van Pel A, Corradin G, Boon T (1992) Mouse tumor rejection antigens P815A and P815B: two epitopes carried by a single peptide. Eur J Immunol 22:2283
14. d by cytolytic T cells. Cell 58:293
15. + T cells. J Immunol 154:5071
16. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Martin Kast W, Deleo AB, Lotze MT (1995) Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1:1297
17. Moriya Y, Sato H, Itoh K, Saito M, Yoshida T, Ishida N (1993) Induction of antitumor L3T4-positive T cells by OK-432 at tumor sites in mice. Cancer Immunol Immunother 36:245
18. Okamoto H, Shoin S, Koshimura S, Shimizu R (1967) Studies on the anticancer and streptolysin S-forming abilities of hemolytic streptococci. Jpn J Microbiol 11:323
19. Okamoto T, Harada M, Tamada K, Yoshida H, Ito O, Kong YY, Takenoyama M, Hirashima C, Matsuzaki G, Nomoto K (1997) The local injection of OK432 can augment the Th 1-type T-cell response in tumor-draining lymph node cells and increase their immunotherapeutical potential. Int J Cancer 70:598
20. Ozaki S, Suginoshita T (1989) Biological response modifier as antigen: OK432-specific T-cell clone as anti-tumor effector cell. Cell Immunol 120:477
21. + Lyt2 T-cells. Cancer Res 50:4630
22. Paglia P, Chiodoni C, Rodolfo M, Colombo MP (1996) Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 183:317
23. Pardoll DM (1994) Tumor antigens: a new look for the 1990s. Nature 369:357
24. + T cell reactivity. Eur J Immunol 24:1446
25. Saito M, Nanjo M, Aonuma E, Noda T, Nakadate I, Ehina T, Ishida N (1984) Activated macrophages are responsible for the tumor-inhibitory effect in mice receiving intravenous injection of OK-432. Int J Cancer 33:271
26. Sallusto F, Lanzavecchia A (1994) Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin-4 and downregulated by tumor necrosis factor α. J Exp Med 179:1109
27. Shirai M, Watanabe S, Nishioka M (1990) Intratumoral injection of OK432 and lymphokine-activated killer activity in peripheral blood of patients with hepatocellular carcinoma. Eur J Cancer 26:965
28. Steinman RM, Swanson J (1995) The endocytic activity of dendritic cells. J Exp Med 182:283
29. Szikora JP, Van Pel A, Brichard V, Andre M, Van Baren N, Henry P, De Plaen E, Boon T (1990) Structure of the gene of tum-transplantation antigen P35B: presence of a point mutation in the antigenic allele. EMBO J 9:1041
30. Tamada K, Harada M, Okamoto T, Takenoyama M, Ito O, Matsuzaki G, Nomoto K (1995) Specific antitumor activity of tumor-infiltrating lymphocytes expanded first in a culture with both anti-CD3 monoclonal antibody and activated B cells and then in a culture with interleukin-2. Cancer Immunol Immunother 41:339
31. Tomai MA, Kotob M, Majumder G, Beachey EH (1990) Superantigenecity of streptococcal M protein. J Exp Med 172:359
32. Torisu M, Katano M, Kimura Y, Itoh H, Takesue M (1983) New approach to management of malignant ascites with a streptococcal preparation, OK-432. Improvement of host immunity and prolongation of survival. Surgery 93:357
33. Uyttenhove C, Maryansky J, Boon T (1983) Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J Exp Med 157:1040
34. Van den Eynde B, Lethe B, Van Pel A, De Plaen E, Boon T (1991) The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J Exp Med 173:1373
35. Watabe S, Sendo E, Kimura S, Arai S (1984) Activation of cytotoxic polymorphonuclear leukocytes by in vivo administration of a streptococcal preparation, OK-432. J Natl Cancer Inst 72:1365
36. Watanabe Y, Iwa T (1984) Clinical value of immunotherapy for lung cancer by the streptococcal preparation, OK-432. Cancer 52:248
37. Young JW, Inaba K (1996) Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J Exp Med 183:7
38. Zilvogel L, Mayordomo JI, Tjandrawan T, Deleo AB, Clarke MR, Lotze MT, Strokus WJ (1996) Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 183:87